Abbott’s Patent Plea for HIV Drug Rejected

4 Jan 2011

After a three-year hearing, India’s patent office has rejected an application filed by US drug multinational Abbott Laboratories for its anti-HIV drug Aluvia, a combination of the drugs lopinavir and ritonavir, according to a copy of the decision seen by Mint on Monday. Livemint

Partner with us now to build
a more just and equitable
medicine system for all.